Global Plasticizer Market Size, Share, Trends And Forecasts To 2018: Radiant Insights, Inc

TechNavio's analysts forecast the Global Plasticizer market to grow at a CAGR of 5.95 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in demand from the Medical industry. The Global Plasticizer market has also been witnessing the growth in environmental concern. However, the health risks associated with plasticizers could pose a challenge to the growth of this market.

TechNavio's report, the Global Plasticizer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the APAC, Europe, North America, MEA, and Latin America regions; it also covers the Global Plasticizer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Enquire About Report: http://www.radiantinsights.com/research/global-plasticizer-market-2014-2018

The key vendors dominating this market space are BASF SE, Eastman Chemical Co., ExxonMobil Corp., and Ferro Corp. Other vendors mentioned in the report are Adeka Corp., Arkema S.A., Clariant International Ltd., Daelim Industrial Co. Ltd., Dow Chemical Co., Evonik Industries AG, Grupa Azoty S.A., LG Chem Ltd., Nan Ya Plastics Corp.,

Perstorp Holding AG, Shandong Hongxin Chemicals Co., Sinopec Ltd., Teknor Apex, and UPC Technology Corp.

To Get Sample Copy of Report visit: http://www.radiantinsights.com/research/global-plasticizer-market-2014-2018#tabs-4

Key questions answered in this report:  

What will the market size be in 2018 and what will the growth rate be?
What are the key market trends? What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst's time when you purchase this market report.
Details are provided within the report.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Info - Radiant Insights

Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Global Rheumatoid Arthritis Drugs Market Size, Share, Trends Analysis And Forecasts to 2015

The Global Rheumatoid Arthritis Drugs Industry Report 2015 is a professional and in-depth study on the current state of the Rheumatoid Arthritis Drugs industry.  The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Rheumatoid Arthritis Drugs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.  

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.  

Enquire About Report: http://www.radiantinsights.com/research/global-rheumatoid-arthritis-drugs-industry-2015-market-research-report

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.The Rheumatoid Arthritis Drugs industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.  

With 270 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 

Table Of Conrtent:

• Industry Overview 
• Definition and Specifications of Rheumatoid Arthritis Drugs 
• Classification of Rheumatoid Arthritis Drugs 
• Applications of Rheumatoid Arthritis Drugs 
• Industry Chain Structure of Rheumatoid Arthritis Drugs 
• Industry Regional Overview of Rheumatoid Arthritis Drugs 
• Industry Policy Analysis of Rheumatoid Arthritis Drugs 
• Industry News Analysis of Rheumatoid Arthritis Drugs  
• Manufacturing Cost Structure Analysis of Rheumatoid Arthritis Drugs 
• Raw Material Suppliers and Price Analysis of Rheumatoid Arthritis Drugs 
• Equipment Suppliers and Price Analysis of Rheumatoid Arthritis Drugs

To Get Sample Copy of Report visit: http://www.radiantinsights.com/research/global-rheumatoid-arthritis-drugs-industry-2015-market-research-report#tabs-4

• Labor Cost Analysis of Rheumatoid Arthritis Drugs 
• Other Costs Analysis of Rheumatoid Arthritis Drugs 
• Manufacturing Cost Structure Analysis of Rheumatoid Arthritis Drugs 
• Manufacturing Process Analysis of Rheumatoid Arthritis Drugs  
• Technical Data and Manufacturing Plants Analysis 
• Capacity and Commercial Production Date of Global Key Manufacturers in 2014 
• Manufacturing Plants Distribution of Global Key Rheumatoid Arthritis Drugs Manufacturers in 2014 
• R&D Status and Technology Source of Global Rheumatoid Arthritis Drugs Key Manufacturers in 2014 
• Raw Materials Sources Analysis of Global Rheumatoid Arthritis Drugs Key Manufacturers in 2014

Media Contact:
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com 
Website: www.radiantinsights.com 

Latest Study - Global Hepatitis B Vaccines Market Size Estimate By 2015: Radiant Insights, Inc.

The Global Hepatitis B Vaccines Industry Report 2015 is a professional and in-depth study on the current state of the Hepatitis B Vaccines industry.  

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Hepatitis B Vaccines market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.  

Read Complete Report With TOC: http://www.radiantinsights.com/research/global-hepatitis-b-vaccines-industry-2015-market-research-report

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.  

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.The Hepatitis B Vaccines industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.  

With 175 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 

Table Of Content:

• Industry Overview 
• Definition and Specifications of Hepatitis B Vaccines 
• Classification of Hepatitis B Vaccines 
• Applications of Hepatitis B Vaccines 
• Industry Chain Structure of Hepatitis B Vaccines 
• Industry Regional Overview of Hepatitis B Vaccines 
• Industry Policy Analysis of Hepatitis B Vaccines 
• Industry News Analysis of Hepatitis B Vaccines  
• Manufacturing Cost Structure Analysis of Hepatitis B Vaccines 
• Raw Material Suppliers and Price Analysis of Hepatitis B Vaccines 
• Equipment Suppliers and Price Analysis of Hepatitis B Vaccines 
• Labor Cost Analysis of Hepatitis B Vaccines 
• Other Costs Analysis of Hepatitis B Vaccines 
• Manufacturing Cost Structure Analysis of Hepatitis B Vaccines 
• Manufacturing Process Analysis of Hepatitis B Vaccines

Browse all Reports Of this Category: http://www.radiantinsights.com/catalog/pharmaceutical

• Technical Data and Manufacturing Plants Analysis 
• Capacity and Commercial Production Date of Global Key Manufacturers in 2014 
• Manufacturing Plants Distribution of Global Key Hepatitis B Vaccines Manufacturers in 2014 
• R&D Status and Technology Source of Global Hepatitis B Vaccines Key Manufacturers in 2014 
• Raw Materials Sources Analysis of Global Hepatitis B Vaccines Key Manufacturers in 2014  
• Production Analysis of Hepatitis B Vaccines by Regions, Technology, and Applications 
• Global Production of Hepatitis B Vaccines by Regions (US, EU, China, Japan, etc.) 2010-2015 
• Global Production of Hepatitis B Vaccines by Technology 2010-2015 
• Global Production of Hepatitis B Vaccines by Applications 2010-2015 
• Price Analysis of Global Hepatitis B Vaccines Key Manufacturers in 2015 
• US Capacity, Production, Price, Cost and Revenue of Hepatitis B Vaccines 2010-2015 
• EU Capacity, Production, Price, Cost and Revenue of Hepatitis B Vaccines 2010-2015 
• Japan Capacity, Production, Price, Cost and Revenue of Hepatitis B Vaccines 2010-2015 
• China Capacity, Production, Price, Cost and Revenue of Hepatitis B Vaccines 2010-2015 
• US Supply, Import, Export and Consumption of Hepatitis B Vaccines 2010-2015 
• EU Supply, Import, Export and Consumption of Hepatitis B Vaccines 2010-2015 
• Japan Supply, Import, Export and Consumption of Hepatitis B Vaccines 2010-2015 
• China Supply, Import, Export and Consumption of Hepatitis B Vaccines 2010-2015

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com 
Website: Radiant Insights

Fetzima (Major Depressive Disorder) Market Size Estimate By 2023: Radiant Insights, Inc.

Summary  

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Fetzima (levomilnacipran) is an SNRI indicated for the treatment of MDD and is only available in the US. It gained FDA approval in July 2013 and was launched in December 2013. The product was developed by Forest (Actavis) following a partnership with Pierre Fabre. 

Read Complete Report with TOC: http://www.radiantinsights.com/research/fetzima-major-depressive-disorder-forecast-and-market-analysis-to-2023 

According to this agreement, Forest Laboratories is responsible for the clinical development and commercialization of Fetzima in the US and Canada, while Pierre Fabre is responsible for manufacturing and supplying the active pharmaceutical ingredient.  

Scope  

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Fetzima including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Fetzima for the US from 2013 to 2023. 
- Sales information covered for the US.  

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of Fetzima performance 
- Obtain sales forecast for Fetzima from 2013-2023 in the US.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Savella (Major Depressive Disorder) Market Analysis And Forecasts to 2023 - New Report Available

Summary  

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. 

The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Brintellix (vortioxetine) is a multimodal antidepressant that is indicated for the treatment of MDD and was co-developed by Lundbeck and Takeda. It gained FDA approval in October 2013 and EMA approval in December 2013. 

Full Report Now Available For Radiant Insights Customer @ http://www.radiantinsights.com/research/brintellix-major-depressive-disorder-forecast-and-market-analysis-to-2023 

Brintellix launched in the US market in January 2014 and its launch in European markets is expected during the second half of 2014 (Lundbeck, press release, December 27, 2013).  

Scope  

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Brintellix including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Brintellix for the top eight countries from 2013 to 2023. 
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.  

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of Brintellix performance  
- Obtain sales forecast for Brintellix from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Brintellix (Major Depressive Disorder) Market Overview and Growth Report to 2023

Summary  

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. 

The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Brintellix (vortioxetine) is a multimodal antidepressant that is indicated for the treatment of MDD and was co-developed by Lundbeck and Takeda. It gained FDA approval in October 2013 and EMA approval in December 2013. 

Full Report Now Available For Radiant Insights Customer @ http://www.radiantinsights.com/research/brintellix-major-depressive-disorder-forecast-and-market-analysis-to-2023 

Brintellix launched in the US market in January 2014 and its launch in European markets is expected during the second half of 2014 (Lundbeck, press release, December 27, 2013).  

Scope  

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Brintellix including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Brintellix for the top eight countries from 2013 to 2023. 
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.  

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of Brintellix performance  
- Obtain sales forecast for Brintellix from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Global PharmaPoint: Migraine Drug Market growth to 2023

Summary  

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. 

By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. 

Enquire About Report: http://www.radiantinsights.com/research/pharmapoint-migraine-global-drug-forecast-and-market-analysis-to-2023 

Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.  

Highlights  

Key Questions Answered  

- The migraine market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? 
Will the drugs under development fulfil the unmet needs of the migraine market? 
- The late-stage migraine pipeline is filled with therapies with diverse formulations and routes of administration. Which drug will have a significant impact on the migraine market. Which of these drugs will have the highest CAGR, and why? 
- The migraine market is currently dominated by generic drugs. How will the introduction of combinations of device and drugs, and new classes of therapies change the treatment landscape once reimbursement is not a problem anymore? 
How will the drug treatment rates change over the next ten years? 
What are the key drivers and barriers to this change?

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

PharmaPoint: Major Depressive Disorder Australia Drug Market 2023 - New Industry Study Published By Radiant Insights, Inc

Summary  

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. 

The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Read Complete Report with TOC: http://www.radiantinsights.com/research/pharmapoint-major-depressive-disorder-australia-drug-forecast-and-market-analysis-to-2023 

Despite patent expiries for key products, Eli Lilly's Cymbalta in 2013, Otsuka Pharmaceutical/BMS's Abilify in 2016, and AstraZeneca's Seroquel XR in 2017, the MDD market value in Australia is not anticipated to decline, as generic products are priced similarly to branded products and any loss of market value due to potential price discounts is expected to be offset by the increasing prevalent cases of MDD, the launch of Brintellix and the potential introduction of late-stage pipeline products during the forecast period.  

Scope  

- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for the top drugs in Australia from 2013-2023. 
- Analysis of the impact of key events as well the drivers and restraints affecting the Australia Major depressive disorder market.  

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder. 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in Australia.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Abilify Market Growth And Forecast To 2023 By Radiant Insights, Inc

Summary  

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. 

The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Click for report details: http://www.radiantinsights.com/research/abilify-major-depressive-disorder-forecast-and-market-analysis-to-2023 

Abilify (aripiprazole) is an atypical antipsychotic indicated for use as an adjunctive treatment for MDD in patients who have not adequately responded to antidepressant therapy in the US. Abilify is available in the 5EU, Japan, and Australia, but is not indicated for the treatment of MDD, and as such, it is being used as an off-label treatment, as validated by GlobalData's primary research survey in January 2014.  

Scope  

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Abilify including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Abilify for the top eight countries from 2013 to 2023. 
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.  

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of Abilify performance 
- Obtain sales forecast for Abilify from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Seroquel XR (Major Depressive Disorder) Market Trends And Segment Forecasts To 2023 - Radiant Insights

Summary  

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Seroquel XR (quetiapine) (extended-release tablets) is an atypical antipsychotic that is indicated as an adjunctive treatment for MDD in the US, 5EU, and Australia. AstraZeneca initially developed the Seroquel immediate release formulation for the treatment of schizophrenia and bipolar disorder, but has not gained regulatory approvals for MDD with Seroquel. 

Click for report details: http://www.radiantinsights.com/research/seroquel-xr-major-depressive-disorder-forecast-and-market-analysis-to-2023 

With the development of Seroquel XR, AstraZeneca expanded the label of this product for the treatment of MDD as an adjunctive therapy, initially in 2009 in the US and Australia, followed by an approval in 2010 in the 5EU.  

Scope  

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Seroquel XR including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Seroquel XR for the top eight countries from 2013 to 2023. 
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.  

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of Seroquel XR performance 
- Obtain sales forecast for Seroquel XR from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Brexpiprazole (Major Depressive Disorder) Market Trends Analysis And Forecasts To 2023 - By Radiant Insights, Inc

Summary  

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. 

The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Otsuka Pharmaceutical initially developed Brexpiprazole but in 2011, the pharmaceutical company entered an agreement with Lundbeck for the co-development and co-commercialization of this product. The product is in Phase III development as an adjunctive therapy for MDD in the US and Europe, and is also being developed for the treatment of schizophrenia, anxiety disorders, dementia, post-traumatic stress disorder (PTSD), sleep disorders, and ADHD.  

Scope  

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Brexpiprazole for the top eight countries from 2013 to 2023. 
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.  

Full Report Now Available For Radiant Insights Customer @ http://www.radiantinsights.com/research/brexpiprazole-major-depressive-disorder-forecast-and-market-analysis-to-2023 

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance 
- Obtain sales forecast for Brexpiprazole from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Chronic Lymphocytic Leukemia Market - Future Growth, Opportunities and Forecast to 2018

Summary  

Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled proliferation of B lymphocytes (a type of white blood cell) in the bone marrow, blood and lymphoid tissues. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the CLL market with coverage of both the first-line and relapsed/refractory settings. 

While the current standard of care consists of chemoimmunotherapy, CLL disease management is poised for dramatic changes, particularly in the treatment of relapsed/refractory and elderly patients, as four new drugs (Gazyva, Imbruvica, idelalisib and IPI-145) will launch during the forecast period. As they address large unmet needs, GlobalData expects these premium-priced new drugs will have rapid uptake driving the overall CLL market and contributing to over 70% of total market sales by 2018.  

Highlights  

Key Questions Answered  

- Which CLL patients have the greatest unmet needs and how well will these needs be addressed by the new agents?

Full Report Now Available For Radiant Insights Customer @ http://www.radiantinsights.com/research/opportunityanalyzer-chronic-lymphocytic-leukemia-opportunity-analysis-and-forecasts-to-2018 

- How will CLL disease management change as new agents enter the market? 
- What are the R&D and clinical trial design strategies pursued by companies in the CLL space? 
- What are the most promising late-stage pipeline agents for CLL? How do their clinical and commercial attributes compare to one another and the current standards of care? 
- What opportunities will remain for future players following the launch of these pipeline agents? 
- What exciting, innovative approaches are being investigated in the early-stage CLL pipeline? 

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Refining Market 2019: Latest Industry Analysis Presented By Radiant Insights

Summary  

"Refining Industry Outlook in Asia and Oceania to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries" is a comprehensive report on crude oil refining industry in Asia and Oceania. 

The report provides refinery details such as refinery name, country, and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all active and planned refineries in the region. 

The report also provides refinery capital expenditure outlook for Asia and Oceania till 2019. The report provides key country comparisons within a region based on contribution to regional refining capacity as well as refining capacity growth. Further, the report also offers recent developments as well as latest tenders and contracts for countries.  

To Get More Details @ http://www.radiantinsights.com/research/refining-industry-outlook-in-asia-and-oceania-to-2019-capacity-and-capital-expenditure-forecasts-with-details-of-all-operating-and-planned-refineries 

Scope  

- Updated information relating to all active and planned refineries 
- Provides historical data from 2009 to 2014, forecast to 2019 
- Information on refining, FCC, hydrocracking and coking capacities by refinery and country 
- Provides operator information for all active and planned refineries 
- Lastest developments and contracts related to refineries across different countries globally.  

Reasons To Buy  

- Obtain the most up to date information available on all active and planned refineries in Asia and Oceania 
- Identify growth segments and opportunities in the industry 
- Facilitate decision making on the basis of strong historic and forecast refinery and unit capacity data 
- Assess your competitor's refining portfolio and its evolution.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Atrial Fibrillation Market 2023 - Share, Analysis and Forecasts Report

Summary  

Atrial fibrillation (AF) is a disorder of the heart's electrical system. AF is one of the most common cardiovascular diseases among the elderly, worldwide. According to the Global Burden of Disease study, AF affected approximately 33.5 million people, or 0.5% of the world's population, in 2010, of which 20.9 million were men and 12.6 million were women. The disease burden is likely to increase in the near future due to the projected increase in the population, especially the elderly population.  GlobalData epidemiologists forecast that the diagnosed prevalent cases of AF in the 8MM will grow by 21.8% over the next decade, from 10,112,797 diagnosed prevalent cases in 2013 to 12,316,458 diagnosed prevalent cases in 2023. 

GlobalData epidemiologists attribute the growth in the diagnosed prevalent cases of AF in the 8MM to the changing population demographics in the respective markets, rather than an actual increase in the diagnosed prevalence of AF in these markets.  

GlobalData's epidemiological forecast for the diagnosed prevalent cases of AF in the 8MM is supported by epidemiologic data from country-specific studies that are nationally representative of the entire population in these markets. 

Read Complete Report with TOC: http://www.radiantinsights.com/research/epicast-report-atrial-fibrillation-epidemiology-forecast-to-2023 

GlobalData's epidemiological analysis included the most recently published nationally-representative studies in the 8MM, which provided the diagnosed prevalence of AF using uniform diagnostic criteria based on EKG tests. Furthermore, the diagnosed prevalent cases of AF in each of the 8MM were further segmented by age and sex to provide a more detailed analysis of the patient population. The distribution of cases segmented by age and sex is important for understanding the burden of AF in various subgroups of the populations in each market, and for achieving better management of the condition.  

Scope  

- The Atrial fibrillation (AF) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of AF in the 8MM (US, France, Germany, Italy, Spain, UK, Japan and Canada). 
It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AF segmented by age (ages =40 years), sex, and clinical subtypes (paroxysmal, persistent, and permanent AF) in these markets. 
- The AF epidemiology report is written and developed by Masters- and PhD-level epidemiologists. 
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Celiac Disease Market to 2023: Drivers, Trends & Growth Analysis By Radiant Insights

Summary  

There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications. 

The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2019 and 2020 in the US and 5EU respectively are set to change the management of the disease and drive growth in the celiac disease market. Both drugs are expected to target patients who undergo gluten exposure while on a GFD equating to approximately 95% of the celiac disease patient population. 

Read Complete Report with TOC: http://www.radiantinsights.com/research/opportunityanalyzer-celiac-disease-opportunity-analysis-and-forecast-to-2023 

GlobalData estimates that the uptake of both drugs will be equally high, but latiglutenase will rapidly gain market value and emerge the commercially stronger drug with the backing of Immune-Gastro veteran AbbVie.  

Highlights  

Key Questions Answered  

- (Q.) How will the celiac disease market landscape change within the 2013-2018 and the 2013-2023 forecast periods in the 6MM? 
- (Q.) What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the celiac disease market? 
- (Q.) How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options? 
- (Q.) What are the significant unmet needs in the celiac disease market? 
- (Q.) What are the remaining opportunities in the celiac disease market?

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

PharmaPoint: Prophylactic Human Papillomavirus Vaccines Canada Drug Market Size, Share, Trends And Forecasts To 2022

Summary  

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. 

In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.  

Full Report Now Available For Radiant Insights Customer @ http://www.radiantinsights.com/research/pharmapoint-prophylactic-human-papillomavirus-vaccines-canada-drug-forecast-and-market-analysis-to-2022 

The anticipated addition of boys to routine HPV vaccine recommendations by different Canadian provinces is expected to serve as a significant driver to growth within the HPV vaccines market in Canada over the forecast period. In addition, from primary research insight, GlobalData projects Merck's nine-valent vaccine V503 to be widely adopted in the country. This will also significantly enhance the size of the HPV vaccines sector in Canada.  

Scope  

- Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on the key drugs in the Canada including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for the top drugs in the Canada from 2012-2022. 
- Analysis of the impact of key events as well the drivers and restraints affecting the Canada Prophylactic Human Papillomavirus Vaccines disease market.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

PharmaPoint: Rheumatoid Arthritis Australia Drug Market 2023 - New Research Report Published By Radiant Insights

Summary  

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. 

The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. 

With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.  The drivers of growth in this market include the increasing RA patient population and the universal healthcare system, as well as the use of technology to connect patients with physicians and speed the process of diagnosis and treatment. Barriers to the growth of the market include government measures to cut healthcare spending, similar to the austerity measures implemented in the 5EU. 

To Get More Details @ http://www.radiantinsights.com/research/pharmapoint-rheumatoid-arthritis-australia-drug-forecast-and-market-analysis-to-2023 

In the RA market in Australia, there are a number of different treatment options available, similar to the 7MM.  

Scope  

- Overview of Rheumatoid arthritis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on the key drugs in the Australia including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for the top drugs in the Australia from 2013-2023. 
- Analysis of the impact of key events as well the drivers and restraints affecting the Australia Rheumatoid arthritis market.  

Reasons To Buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid arthritis 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the Australia.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com